Directed issue registered at the Companies Registration Office

Phase Holographic Imaging PHI AB (“PHI” or “the Company”) Board of Directors’ proposal on a directed issue to Altium S.A. was resolved on the extraordinary general meeting on November 15, 2023. The directed issue has now been registered at the Swedish Companies Registration Office.

Shares and share capital

The directed issue has resulted in an increase of 2,374,820 shares and SEK 474,964.00 in share capital. After the issue, the total number of shares amounts to 26,192,925 shares and the share capital amounts to SEK 5,238,585.00.

Flagging

Through the directed issue, Altium S.A. has increased its ownership from 4,071,707 shares to 6,446,527 shares. The ownership has thus gone from approx. 17.1% of the total number of shares in the Company, to approx. 24.6% of the total number of shares in the Company.

For additional information, please contact:
Patrik Eschricht
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis

Phase Holographic Imaging (PHI) develops instrumentation and software for time-lapse cytometry. The products are used for long-term quantitative analysis of the dynamics of live cells, particularly significant in the research of cancer, as well as in the treatment of inflammatory and autoimmune diseases. The products are sold globally through the company's distributors. The company is based in Lund, Sweden, and in Boston, Massachusetts.